ClinicalTrials.gg
RecruitingNCT05401032TryptoBPHUpdated Jan 6, 2025

Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.

A Phase 2 interventional study of Tamsulosin and 5-hidroxitriptophan in BPH and LUTS(Lower Urinary Tract Symptoms), sponsored by Clinical Academic Center (2CA-Braga). Recruiting at 1 site in Portugal. Open to male participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-01-06.

Sponsored by Clinical Academic Center (2CA-Braga) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
50 Years to 74 Years
Sex
Male
01

Study summary

Benign prostatic hyperplasia (BPH) is one of the most prevalent human diseases and a major cause of lower urinary tract symptoms (LUTS). Some men respond to current medical treatment (mainly α-1 adrenoreceptor antagonists and 5 α-reductase inhibitors), but a large proportion of patients continues to need a surgical procedure to treat resistant LUTS or even more serious complications of BPH, creating the emerging necessity for novel pharmacological therapies.

Oxitriptan may have a possible positive effect on BPH associated symptoms with probably no impact in sexual function (which is a common side effect of the current drugs for BPH associated symptoms). Also, improvement in symptoms could be higher than that of current drugs used for this condition.

This is a single-center parallel group, randomized clinical trial. The study will take place in Hospital de Braga (Urology department). Eligible patients will be randomized to receive tamsulosin 0.4mg (once a day, q.d.) or 5-HTP (5-hidroxitriptophan) 100mg (three times a day, t.i.d.), for 6 months.

02

Conditions studied

  • BPH
  • LUTS(Lower Urinary Tract Symptoms)

Keywords

  • BPH
  • LUTS
  • 5-HTP
  • Oxitriptan
  • Tamsulosin
03

In context

Lower Urinary Tract Symptoms

419 studies on the registry are indexed under Lower Urinary Tract Symptoms; 110 are open to participants now.

This study's planned enrollment of 70 is below the median of 100 across 273 interventional studies indexed under Lower Urinary Tract Symptoms.

Browse Lower Urinary Tract Symptoms studies →

Lead sponsor

Clinical Academic Center (2CA-Braga) is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 74 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ;
  • Male patients with BPH for which tamsulosin is the therapeutic option per SoC;
  • Aged ≥50 and less than 75 years old;
  • With prostate volume ≥30 cm3 by TRUS;
  • Diagnosed with LUTS defined by a stable IPSS total score ≥13 points.

Exclusion criteria

Exclusion Criteria:

  • Patients with post-void bladder residual volume ≥250 ml;
  • Patients with intravesical obstruction from any cause other than BPH;
  • History of any procedure considered an intervention for BPH;
  • Patients with active urinary tract infection;
  • History of recurrent urinary tract infections;
  • Current prostatitis or diagnosis of chronic prostatitis;
  • History of prostate or invasive bladder cancer;
  • Use of 5 α-reductase inhibitors within 6 months;
  • Phytotherapy within 2 weeks before entry;
  • Use of serotonin reuptake inhibitors or monoamine oxidase inhibitors;
  • Patients with acute or chronic kidney failure;
  • Patients with diagnosed or suspicion of intolerance to lactose;
  • Patients submitted to general anesthesia in the past 4 weeks;
  • Known intellectual disability that may hampers giving and would make the patient inappropriate for entry into this study, in the judgment of the investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Control arm

    tamsulosin 0.4mg (once a day) for 6 months.

    Drug: Tamsulosin

  • Experimental
    Experimental arm

    5-hidroxitriptophan 100 mg (3 times a day) for 6 months.

    Drug: 5-hidroxitriptophan

Interventions

  • Oral medication, once a day for 6 months.

    Also known as: Omnic

  • Drug5-hidroxitriptophan

    Oral medication, 3 times a day for 6 months.

    Also known as: Cincofarm

06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score (IPSS)

    Evaluate the effect of tryptophan supplementation on lower urinary tract symptoms (LUTS)

    Time frame: Change from baseline to day 1, 1-month, 3- month and EOT (6-month)

Secondary outcomes

  1. Qmax

    Urine maximum flow rate

    Time frame: Change from baseline to EOT (6-month)

  2. IIEF-5

    Erectile function, assessed by International Index of Erectile Function-5 (IIEF-5)

    Time frame: Change from baseline to EOT (6-month)

  3. Prostate volume

    Prostate volume (in cc), assessed by trans-rectal ultra-sound

    Time frame: Change from baseline to EOT (6-month)

  4. question 8 of the IPSS

    quality of life due to urinary symptoms (question 8 of the IPSS).

    Time frame: Change from baseline to EOT (6-month)

07

Study locations

1 of 1 sites recruiting
  • Clinical Academic Center - Braga, Association (2CA-Braga)
    Braga, 4710-243, Portugal
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
Jun 2, 2022
StartActual
Dec 20, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05401032
Lead sponsor
Clinical Academic Center (2CA-Braga)
Responsible party
Sponsor
First posted
Jun 2, 2022
Start date
Dec 20, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 6, 2025

Study contacts

Mónica Gonçalves
Contact
2ca@ccabraga.org
+351 253 027 249
Rosana Magalhães
Contact
cro@ccabraga.org
+351 253 027 249
Emanuel Dias
principal investigator · Hospital de Braga

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion